198 related articles for article (PubMed ID: 29189158)
1. Cancer Targeted Therapy Strategy: The Pathologist's Perspectives.
Alessandrini L; Perin T; Kadare S; Del Pup L; Memeo L; Steffan A; Colarossi L; Berretta M; De Paoli P; Canzonieri V
Curr Cancer Drug Targets; 2018; 18(5):410-420. PubMed ID: 29189158
[TBL] [Abstract][Full Text] [Related]
2. Molecular targets in GI malignancies - A pathologist's perspective.
Pawar S; Sharma A
Indian J Pathol Microbiol; 2021 Jun; 64(Supplement):S43-S51. PubMed ID: 34135137
[TBL] [Abstract][Full Text] [Related]
3. [Molecular tumor board in uro-oncology-from a pathologist's view].
Gaisa NT; Kristiansen G; Perner S
Urologe A; 2019 Jul; 58(7):747-751. PubMed ID: 31049636
[TBL] [Abstract][Full Text] [Related]
4. [Personalized medicine in haematooncology--the pathologist's perspective].
Campr V
Cas Lek Cesk; 2010; 149(10):464-7. PubMed ID: 21121135
[TBL] [Abstract][Full Text] [Related]
5. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
[TBL] [Abstract][Full Text] [Related]
6. [Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view].
Bibeau F; Frugier H; Denouel A; Sabourin JC; Boissiere-Michot F
Bull Cancer; 2009 Dec; 96 Suppl():S15-22. PubMed ID: 20034866
[TBL] [Abstract][Full Text] [Related]
7. [The pathologist's role in the neoadjuvant strategy of renal-cell carcinoma].
Leroy X; Edeline J; Rioux-Leclercq N
Ann Pathol; 2011 Dec; 31(6):466-71. PubMed ID: 22172119
[TBL] [Abstract][Full Text] [Related]
8. A Brief History, the Progress in the Variants of Therapies against Metastatic Neoplasms, and the Role of Pathologists.
Zhang KJ; Qu Z; Zhang PL; Brown RE
Ann Clin Lab Sci; 2021 Jul; 51(4):461-469. PubMed ID: 34452884
[TBL] [Abstract][Full Text] [Related]
9. Editorial: The Real Impact of Target Therapy in Cancer Patients: Between Hope and Reality.
Berretta M; Di Francia R
Curr Cancer Drug Targets; 2018; 18(5):402-404. PubMed ID: 29956604
[No Abstract] [Full Text] [Related]
10. Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer.
Kruglyak KM; Lin E; Ong FS
Adv Exp Med Biol; 2016; 890():123-36. PubMed ID: 26703802
[TBL] [Abstract][Full Text] [Related]
11. Digital pathology in personalized cancer therapy.
Słodkowska J; Rojo MG
Folia Histochem Cytobiol; 2011; 49(4):570-8. PubMed ID: 22252751
[TBL] [Abstract][Full Text] [Related]
12. The possibility of clinical sequencing in the management of cancer.
Kou T; Kanai M; Matsumoto S; Okuno Y; Muto M
Jpn J Clin Oncol; 2016 May; 46(5):399-406. PubMed ID: 26917600
[TBL] [Abstract][Full Text] [Related]
13. Lung cancer genotype-based therapy and predictive biomarkers: present and future.
Cagle PT; Allen TC
Arch Pathol Lab Med; 2012 Dec; 136(12):1482-91. PubMed ID: 23194040
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy.
Di Francia R; De Monaco A; Saggese M; Iaccarino G; Crisci S; Frigeri F; De Filippi R; Berretta M; Pinto A
Curr Cancer Drug Targets; 2018; 18(5):499-511. PubMed ID: 28183252
[TBL] [Abstract][Full Text] [Related]
15. Liquid biopsy for predictive mutational profiling of solid cancer: The pathologist's perspective.
Méhes G
J Biotechnol; 2019 May; 297():66-70. PubMed ID: 30953676
[TBL] [Abstract][Full Text] [Related]
16. Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's Perspective.
Brega E; Brandao G
Front Oncol; 2014; 4():182. PubMed ID: 25077070
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers and biomarker validation: a pathologist's guide to getting it right.
Paver EC; Morey AL
Pathology; 2024 Mar; 56(2):147-157. PubMed ID: 38195376
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of Pathologist's Routine Practice: Reuse of DNA Extracted from Immunostained Formalin-fixed Paraffin-embedded (FFPE) Slides in Downstream Molecular Analysis of Cancer.
Al-Attas A; Assidi M; Al-Maghrabi J; Dallol A; Schulten HJ; Abu-Elmagd M; Chaudhary A; Abuzenadah A; Budowle B; Buhmeida A; Al-Qahtani M
Cancer Genomics Proteomics; 2016 09-10; 13(5):399-406. PubMed ID: 27566658
[TBL] [Abstract][Full Text] [Related]
19. Personalized Medicine: Genomics Trials in Oncology.
Hayes DF; Schott AF
Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
[TBL] [Abstract][Full Text] [Related]
20. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
